Tandem Diabetes Care (TNDM) posted its strongest quarter in some time. It reported a loss of $0.10 per share against a consensus estimate of -$0.27, a 63.0% earnings surprise. Revenue rose 13.8% year over year to $283.69 million, topping the $265.29 million consensus by 6.9%. Earnings grew 67.7% from a year ago as the net loss narrowed from $21.2 million ($0.31 per share) to $7.1 million. Growth accelerated sharply: sales rose about 14% after just 6% growth in the second quarter. That is the central tension. The quarter Tandem just reported was better than almost anyone modeled, but management used the call to lower expectations for the year ahead.

The quality of the beat is largely genuine. U.S. sales of $191.0 million rose 9% and beat the company's own $180 million guide. International sales reached a record $92.6 million, up 26% against an $85 million guide. Gross margin climbed 270 basis points to 57%. Operating expenses grew only about 4%, so the operating loss shrank to $2.4 million from $22.9 million. Adjusted EBITDA reached $18.0 million, or 6% of sales, versus roughly 2% guided. That was the fifth straight positive quarter. Two caveats apply:

• **Lower stock compensation.** Stock-based compensation fell to $15.9 million from $21.1 million, which flatters the GAAP improvement.
• **Weaker cash generation.** Free cash flow swung to -$5.5 million from +$4.2 million a year earlier. Management attributed this to an infusion-set inventory rebuild and capital spending.

Beneath the headline, the business model is visibly shifting. U.S. pump revenue actually fell 2% even though U.S. shipments rose to nearly 23,000 from just over 20,000. Meanwhile, U.S. supplies and other revenue jumped 19%. That pattern reflects the pay-as-you-go pharmacy model, which moves revenue away from upfront pump sales and toward recurring supplies. Pharmacy formulary coverage reached about 50% of U.S. lives, up from 33% at the end of 2025. Pharmacy accounted for 15% of U.S. sales, up from 10% in the second quarter. Management said pharmacy supply pricing is averaging closer to $400 per month, versus a $350 modeling baseline. Demand also improved. U.S. new pump starts returned to year-over-year growth after declining in the first quarter and being nearly flat in the second. Conversions from multiple daily injections (MDI) made up roughly 70% of new starts and grew nearly 10%.

The forward picture is where bears have legitimate ammunition:

• **Pharmacy assumptions cut.** Management lowered its full-year pharmacy pump share assumption to 10-12% from roughly 20%, and its pharmacy share of U.S. sales to 10-12% from 15%. That pushes transition headwinds into 2027.
• **2027 growth reset.** Management called mid-to-high single-digit growth a "fair starting point" for 2027 and asked analysts to recalibrate. Consensus stood near 12%, and earlier in the year the company had talked about accelerated growth in 2027.
• **Mobi Tubeless delay.** Full availability slipped from a scaled second-half 2026 launch to the first half of 2027, with an initial label covering abdominal wear only.
• **Supply and reimbursement setbacks.** Infusion-set shortages are now expected to persist into early 2027. The CMS C-peptide decision for type 2 diabetes missed its expected August timing.
• **Leadership change.** CEO John Sheridan retires at year-end, and Jeanette Bankas joins November 16, in the middle of a business-model transition.

On guidance, Tandem reaffirmed 2026 sales of $1.065 billion to $1.085 billion, gross margin of 56-57%, and an adjusted EBITDA margin of 5-6%. It did not raise the outlook despite the third-quarter outperformance, citing pharmacy uncertainty. One summary of the call cited a worldwide range of $1.65-1.85 billion. That figure appears to be an error, because the stated U.S. and international ranges sum to the release's roughly $1.07-1.09 billion. On the catalyst side:

• **Closed-loop study.** A fully closed-loop pivotal study is slated to begin in the fourth quarter, targeting a 2028 launch.
• **International expansion.** Direct operations in France will take direct coverage above 30% of the international base. The direct channel already rose to 18% of international revenue from 11% in the first quarter.

Investors were not leaning bullish heading into the print. Earnings Whispers sentiment stayed negative and weakened modestly, from -0.12 to -0.20. Shares were at $19.05 before the report, up 9.5% from the $17.39 open after the August release. The ride was volatile: the stock spiked to $24.81 on August 19, then collapsed to $14.83 by late September. It entered earnings 23% below that high and 28.5% above the low, squarely mid-range. Most Earnings Whispers trend readings, including sequential growth and momentum, are positive, though the price trend remains negative.

The bottom line is that Tandem delivered a quarter that turnaround skeptics were not positioned for. Growth accelerated, margins expanded, U.S. new starts recovered, and international reached a record. However, the company paired that with a slower pharmacy conversion path, a delayed Mobi Tubeless launch, lingering supply constraints, and a 2027 framing that resets consensus lower. The strong quarter improves confidence in execution and profitability, while the guidance reset pushes the payoff from the pharmacy model further out. A new CEO will now inherit that tradeoff.